Landmark study by AO Spine NA researcher published in The Lancet Neurology

Michael Fehlings, MD “Safety and Efficacy of Riluzole” article in distinguished journal

08 January 2021

AO Spine NA would like to congratulate Principal Investigator Michael Fehlings, MD (Department of Neurosurgery, University of Toronto) and his colleagues for the publication of the landmark study, Safety and Efficacy of Riluzole in Patients Undergoing Decompressive Surgery for Degenerative Cervical Myelopathy (CSM-Protect): A Multicentre Double-Blind, Placebo-Controlled, Randomised Phase 3 Trial, in The Lancet Neurology. 

Having their clinical study published in this highly respected journal demonstrates the importance of the research. Dr. Fehling's work was funded by AO Spine North America.

Related pages

AO Spine NA


Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.